Please ensure Javascript is enabled for purposes of website accessibility

Why Prana Biotechnology Limited and Medbox Inc. Lost Big Today

By Dave Williamson - Feb 19, 2014 at 6:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One biotech and one player in the new marijuana industry that fell hard today.

Prana Biotechnology Limited (NASDAQ: PRAN) and Medbox Inc. (NASDAQOTH: MDBX) were the big losers in the health-care space today, and in this segment from Wednesday's Market Checkup, Motley Fool health-care analyst David Williamson looks at what caused these two market nosedives.

Prana released phase 2 trial results for its leading drug candidate PBT2 in its Huntington's disease indication. While the drug hit its safety endpoint, there is still considerable debate over the drug's efficacy, with the company calling the trial a success, while critics looking at the overall data have called it a failure. Shares are down 10% on the news. David discusses the future of Prana and PBT2 in both its Huntington's and Alzheimer's disease indications, and advises investors to be sure they know the risks involved here.

Also, Medbox Inc. took a verbal lashing from the famed bearish blog Citron Research today, driving shares down by 7%. The company offers marijuana dispensing machines and consulting services for distributors, and in the video, David notes that he's surprised the stock isn't down further after Citron called it "worthless," and attacked both the validity of the company's financials and the history of its CEO. David advises that while many investors are very eager today to get in on the ground floor of the potential future marijuana sales boom, that the risks involved in this yet uncertain industry are still extremely high, and that waiting until the dust settles further could be a very wise move.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
344%
 
S&P 500 Returns
120%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.